Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma
Status:
Recruiting
Trial end date:
2022-07-30
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind multi-center, phase III study comparing the efficacy and
safety of sintilimab or placebo in combination with chemotherapy as first-line treatment in
subjects with unresectable, locally advanced recurrent or metastatic esophageal squamous cell
carcinoma.